Biolife solutions stock.

Consensus BioLife Solutions, Inc. Equities. BLFS. US09062W2044. Market Closed - Nasdaq. Other stock markets.BOTHELL, Wash., Aug. 8, 2019 / PRNewswire / -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that it has executed a share exchange agreement to effect the acquisition of SAVSU Technologies, a leading developer of advanced ...BioLife Solutions stock scales 10% on acquisition of Stirling Ultracold SA News Mon, Mar. 22, 2021 4 Comments BioLife Solutions EPS misses by $0.01, beats on revenueThe estimated net worth of Marcus Schulz is at least $465,171.85 as of August 25th, 2023. Mr. Schulz owns 42,097 shares of BioLife Solutions stock worth more than $465,172 as of November 2nd. This net worth approximation does not reflect any other investments that Mr. Schulz may own. Learn More about Marcus Schulz's net worth.

BioLife Solutions, Inc. (NASDAQ:BLFS) Q3 2023 Earnings Call Transcript November 9, 2023 BioLife Solutions, Inc. beats earnings expectations. Reported EPS is $-0.3, expectations were $-0.38. Operator: Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Third Quarter 2023 Shareholder and Analyst ... BioLife Solutions is reaffirming 2023 revenue guidance, which is based on expectations for its existing business. Total revenue for 2023 is expected to range from $188 million to $202 million ...

CEO Mike Rice Elected Chairman. BOTHELL, Wash., July 14, 2021 / PRNewswire / -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced changes to its board of directors.

You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.10 Mar, 2023, 15:38 ET. BOTHELL, Wash., March 10, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS ), a leading supplier of class-defining bioproduction tools and services for the cell ...In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on BioLife Solutions. The company’s shares closed last Thursday at $12.42, close to its 52-week low of $12.11.Culture supplement to replace FBS or AB Serum. Biodefined composition reduces lot-to-lot variability. Supports a wide range of cell types including MSCs, T-Cells, NK Cells, Endothelial cells, and more. Promotes improved in vitro and In vivo cell quality in CAR-T applications. Typically used at concentrations ranging from 2% to 10%.BioLife Solutions stock quote and BLFS charts. Latest stock price today and the US's most active stock market forums.

Dec 4, 2023 · Biolife Solutions Inc (NASDAQ:BLFS) has a beta value of 1.60 and has seen 2.24 million shares traded in the last trading session. The company, currently valued at $596.91M, closed the last trade at $13.25 per share which meant it gained $0.88 on the day or 7.11% during that session. The BLFS stock ...

Discover historical prices for BLFS stock on Yahoo Finance. View daily, weekly or monthly format back to when BioLife Solutions, Inc. stock was issued.

BOTHELL, Wash., Nov. 4, 2021 / PRNewswire / -- BioLife Solutions, Inc. (the "Company") (Nasdaq: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced changes to its executive management team, effective immediately.The estimated net worth of Roderick de Greef is at least $463,582.14 as of November 30th, 2022. Mr. de Greef owns 34,314 shares of BioLife Solutions stock worth more than $463,582 as of November 20th. This net worth estimate does not reflect any other investments that Mr. de Greef may own.Sep 1, 2021 · BOTHELL, Wash., Sept. 1, 2021 / PRNewswire / -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has closed its acquisition of Sexton Biotechnologies ... BioLife Solutions Inc. Watch NEW Set a price target alert After Hours Last Updated: Nov 24, 2023 4:04 p.m. EST Delayed quote $ 14.00 -0.08 -0.57% After Hours Volume: 1.96K …Broadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, New York 11717 USA (877) 830 - 4936 [email protected] Solutions, Inc. is a life sciences company. The Company develops, manufactures, and markets bioproduction tools and services which are designed to de-risk biologic manufacturing, storage, distribution, and transportation in the cell and gene therapy (CGT) industry and broader biopharma markets.

The estimated net worth of Andrew G. Hinson is at least $207,858.00 as of June 15th, 2021. Mr. Hinson owns 17,675 shares of BioLife Solutions stock worth more than $207,858 as of November 3rd. This net worth approximation does not reflect any other investments that Mr. Hinson may own. Learn More about Andrew G. Hinson's net worth.BioLife Solutions Reports Third Quarter 2023 Financial Results. BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading supplier of biopreservation media and other cell processing tools and biostorage services for the cell and gene... Nov 02, 2023.BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and …BOTHELL, Wash., Oct. 4, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced a broad engagement with a leading cell therapy developer, wherein BioLife's CryoStor freeze …SenseAnywhere: Cloud-based Monitoring Solutions. Users can connect any number of refrigerators, ULT freezers, and cryogenic freezers to view performance data in one SenseAnywhere account. SenseAnywhere is 21 CFR part 11 compliant and EN12830-2018. Users can download temperature records for audit trail purposes and Good …May 2, 2023 · BOTHELL, Wash., May 2, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's first quarter financial results will be released after market close on Wednesday, May 10, 2023. hace 14 horas ... Institutional investors own 93.24% of the company's stock. Get BioLife Solutions alerts: BioLife Solutions Stock Up 7.1 %. Shares of NASDAQ ...

BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to break-even earnings per share a year ago.Cell Thawing and Transport System for Optimal Thaw Rate. The ThawSTAR CFT2 Cell Thawing System accommodates a 1.8 – 2.0 mL cryogenic vial. The ThawSTAR CFT1.5 Cell Thawing System accommodates a 1.5 mL cryogenic vial. ThawSTAR AT6 Transport and Thawing System for AT-Closed Vial improves the overall handling of biosamples by …

Chg %. Market Cap. Evogene Ltd. -0.32%. $32.76M. BLFS | Complete BioLife Solutions Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full …CryoStor®CS10 effectively mitigates temperature-induced molecular cell stress responses to maximize post-thaw viability and recovery for a variety of immune cell types, including T cells (data not shown) and B cells. Here, human B cells from 6 different donors cryopreserved in CryoStor®CS10 show reproducibly high viability after thawing, as ...Discover historical prices for BLFS stock on Yahoo Finance. View daily, weekly or monthly format back to when BioLife Solutions, Inc. stock was issued. Dec 1, 2023 · View BioLife Solutions, Inc BLFS investment & stock information. Get the latest BioLife Solutions, Inc BLFS detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. BioLife Solutions Company Stats. As of December 2020. Industry Health Care Equipment & Services. ... BioLife Solutions (BLFS) Stock Key Data. Summary Additional Data …Dec 1, 2023 · BioLife Solutions (NASDAQ:BLFS) and Zynex (NASDAQ:ZYXI) are both small-cap medical companies, but which is the superior stock?We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership, media sentiment and community ranking. With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.

Nov. 4, 2021, 04:05 PM. BOTHELL, Wash., Nov. 4, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (the "Company") (Nasdaq: BLFS), a leading supplier of class-defining bioproduction tools and services ...

BOTHELL, Wash., Nov. 4, 2021 / PRNewswire / -- BioLife Solutions, Inc. (the "Company") (Nasdaq: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced changes to its executive management team, effective immediately.

References throughout this Form 10-K to “BioLife Solutions, Inc. ... Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all of the other information contained in this Annual Report, before deciding to invest in our common stock. ...If you’re looking to donate plasma, Biolife Plasma Centers are a fantastic option. They offer convenient locations, a streamlined donation process, and compensation for your time. In this comprehensive guide, we’ll cover everything you need...Are you tired of spending endless hours searching for high-quality stock photos only to discover that they come with a hefty price tag? Look no further. In this article, we will explore the best sources for high-quality really free stock ph...The current BioLife Solutions [ BLFS] share price is $13.57. The Score for BLFS is 44, which is 12% below its historic median score of 50, and infers higher risk than normal. BLFS is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.BOTHELL, Wash., Aug. 8, 2019 / PRNewswire / -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that it has executed a share exchange agreement to effect the acquisition of SAVSU Technologies, a leading developer of advanced ...Biolife Solutions stock has received a consensus rating of buy. The average rating score is and is based on 8 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for Biolife ...BioLife Solutions is introducing initial 2023 revenue guidance, which is based on expectations for its existing business. Expected growth rates are all based on preliminary unaudited revenue. Total revenue for 2023 is expected to range from $188 million to $202 million, reflecting year-over-year growth of 16% to 25%. Excluding COVID related ...Four times named as one of the top 100 Companies to work for in Washington state (2022, 2020, 2015, and 2013), BioLife Solutions Inc. is a multi-platform provider of bioproduction tools and services to the cell and gene therapy and broader biopharma markets. Learn more.Get the latest BioLife Solutions, Inc. (BLFS) stock news and headlines to help you in your trading and investing decisions.BioLife Solutions, Inc. announced that it has received $10.374976 million in funding from Casdin Capital, LLC. Oct. 18. CI. Lake Street Adjusts Price Target on BioLife Solutions to $25 From $34, Maintains Buy Rating. Aug. 09. MT. Transcript : BioLife Solutions, Inc., Q2 2023 Earnings Call, Aug 08, 2023. Aug. 08.BOTHELL, Wash., Oct. 4, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced a broad engagement with a leading cell therapy developer, wherein BioLife's CryoStor freeze …

Wall Street Stock Market & Finance report, prediction for the future: You'll find the Biolife Solutions share forecasts, stock quote and buy / sell signals below. According to present data Biolife Solutions's BLFS shares and potentially its market environment have been in bearish cycle last 12 months (if exists).BioLife Solutions is trading near 52-week lows as its growth story has floundered and profitability remains uncertain. Learn why I rate BLFS stock a hold.Company profile page for BioLife Solutions Inc including stock price, company news, executives, board members, and contact informationInstagram:https://instagram. t rowe health sciencesnvax wsjkennedy dollar coin valueess battery stock The estimated net worth of Marcus Schulz is at least $465,171.85 as of August 25th, 2023. Mr. Schulz owns 42,097 shares of BioLife Solutions stock worth more than $465,172 as of November 2nd. This net worth approximation does not reflect any other investments that Mr. Schulz may own. Learn More about Marcus Schulz's net worth. nyse pkgssnc BLFS: Raising target price to $10.00 BIOLIFE SOLUTIONS INC has an Investment Rating of SELL; a target price of $10.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety... hostesscakes com BioLife Solutions, Inc. Common Stock (BLFS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Hedge fund activity in BioLife Solutions, Inc. (NASDAQ:BLFS) Heading into the second quarter of 2020, a total of 9 of the hedge funds tracked by Insider Monkey were long this stock, a change of ...BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.